This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing.
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Division of Urologic Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN
Professor, Division of Medical Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington School of Medicine
Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Professor of Medicine and Urology, Weill Cornell Medicine
Weill Cornell Medical Center, New York, NY
Attending Physician, New York Presbyterian
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum.
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Division of Urologic Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN
Professor, Division of Medical Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington School of Medicine
Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Professor of Medicine and Urology, Weill Cornell Medicine
Weill Cornell Medical Center, New York, NY
Attending Physician, New York Presbyterian
Hematology-oncologist Specialist
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, OH
Clinical Oncology Pharmacy Specialist
Baptist Health System
Lexington, KY
This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus.
Medical Oncologist
Gastrointestinal Oncology Service, Department of Medicine
Memorial Sloan Kettering Cancer Center, New York, NY
Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
San Francisco, CA
Professor of Radiology, Medicine and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chair, Image-Guided Therapy, Department of Radiology
Northwestern University, Chicago, IL